Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Short Interest Down 21.5% in January

Posted by Latisha Jones on Feb 15th, 2026

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC – Get Free Report) was the recipient of a large drop in short interest in the month of January. As of January 30th, there was short interest totaling 40,324 shares, a drop of 21.5% from the January 15th total of 51,341 shares. Based on an average daily trading volume, of 43,196 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.2% of the shares of the stock are short sold. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 43,196 shares, the days-to-cover ratio is presently 0.9 days.

Oaktree Acquisition Corp. III Life Sciences Stock Performance

Shares of Oaktree Acquisition Corp. III Life Sciences stock traded up $0.05 on Friday, reaching $10.63. 304 shares of the stock were exchanged, compared to its average volume of 29,520. The firm’s 50 day moving average is $10.62 and its 200-day moving average is $10.55. Oaktree Acquisition Corp. III Life Sciences has a one year low of $9.99 and a one year high of $10.85.

Institutional Investors Weigh In On Oaktree Acquisition Corp. III Life Sciences

A number of large investors have recently modified their holdings of the business. Clear Street LLC raised its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 265.1% during the 2nd quarter. Clear Street LLC now owns 22,000 shares of the company’s stock worth $230,000 after buying an additional 15,975 shares in the last quarter. Clear Street Group Inc. acquired a new stake in Oaktree Acquisition Corp. III Life Sciences in the third quarter valued at about $231,000. Readystate Asset Management LP bought a new position in Oaktree Acquisition Corp. III Life Sciences in the third quarter valued at about $262,000. Meteora Capital LLC acquired a new position in Oaktree Acquisition Corp. III Life Sciences during the second quarter worth about $517,000. Finally, Radcliffe Capital Management L.P. bought a new position in shares of Oaktree Acquisition Corp. III Life Sciences in the second quarter worth about $856,000.

Oaktree Acquisition Corp. III Life Sciences Company Profile

(Get Free Report)

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.